本页面由Tiger Trade Technology Pte. Ltd.提供服务

Lyell Immunopharma, Inc.

8.35
-0.3650-4.19%
成交量:4.72万
成交额:40.27万
市值:2.04亿
市盈率:-0.71
高:8.69
开:8.63
低:8.35
收:8.71
52周最高:45.00
52周最低:8.21
股本:2,450.44万
流通股本:1,079.14万
量比:0.38
换手率:0.44%
股息:- -
股息率:- -
每股收益(TTM):-11.8281
每股收益(LYR):-16.0562
净资产收益率:-93.28%
总资产收益率:-34.18%
市净率:0.87
市盈率(LYR):-0.52

数据加载中...

2026/09/10

重要事件披露

Form 8-K - Current report
2026/08/14

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/07/18

SEC问询函

Form CORRESP - Correspondence
2026/06/18

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/06/15

重要事件披露

Form 8-K - Current report
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/11

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/08

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/07

重要事件披露

Form 8-K - Current report
2026/04/21

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/04/13

SEC问询函

Form CORRESP - Correspondence
2026/03/13

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/03/13

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/13

重要事件披露

Form 8-K - Current report
2026/03/09

重要事件披露

Form 8-K - Current report
2025/12/12

SEC问询函

Form CORRESP - Correspondence
2025/12/08

重要事件披露

Form 8-K - Current report